US6047491013
US6047491013
Mirum Pharmaceuticals, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 5.58B EUR | 7.58B EUR | 5.63B EUR | 4.1B EUR |
Enterprise Value | 5.61B EUR | 8.01B EUR | 5.63B EUR | 4.12B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -248.1x | -- | -- | -- |
Price to Sales | 9.04x | 12.27x | 9.88x | 10x |
Price to Book | -- | -- | 23.21x | 13.03x |
EV/Revenue | 9.07x | 12.96x | 9.88x | 10.06x |
EV/EBITDA | -79.78x | -- | -- | 194.38x |
Price to FCF (P/FCF) | 72.89x | -- | -- | 72.08x |
EV/FCF | 73.18x | -- | -- | 72.48x |
FCF Yield | 1.37% | -3.48% | -3.24% | 1.39% |